Infinity undertakes no obligation to publicly update or revise any ofthe

Infinity undertakes no obligation to publicly update or revise any ofthe forward-looking statements. For a more detailed discussion of some of theforegoing risks and uncertainties which could cause actual results to differfrom those contained in the forward-looking statements, see Infinity's filingswith the Securities and Exchange Commission.Conference CallThe Company will hold a conference call to discuss first quarter 2009 resultsat 11:00 a.m (ET) today, April 30. There are two alternative communicationmodes available to listen to the call. Telephone access will be available bydialing 1-888-713-4218 and providing the confirmation code 84467190.Pleasedial 5 to 10 minutes prior to the scheduled start time.

A replay of the callwill also be available one hour following the completion of the call, ataround 1:00 p.m (ET), and will run until 8:00 p.m. on Thursday, May 7, 2009.To listen to the replay, dial 1-888-286-8010 and provide the confirmation code13011787.The conference call will also be broadcast live over the Internet.To listen to the call via the Internet, go to Infinity's website, http://, click on Investor Relations and follow the instructionsat the webcast link. . SCOTTSDALE, AZ, Apr 30 (MARKET WIRE) -- ImmuneRegen BioSciences(R), a wholly owned subsidiary of IR BiosciencesHoldings Inc. (OTCBB: IRBS), is pleased to announce that recent studiesutilizing Homspera(R) confirm the compound stimulates a broad andlong-lasting immune response in animals, as well as, provides protectionagainst intracellular pathogens.Specifically, the active component of Homspera, an agonist of theneurokinin-1 receptor (NK1R), among other immunostimulatory activities,promotes the activation and migration of skin dendritic cells (DCs) tolymph nodes to induce functional antigen specific cellular immunity,including CD4+ T-helper 1 cells (Th1) and CD8+ cytotoxic T-lymphocyte(CTL) responses.

In addition, the NK1R agonist promotes the survival ofDCs in vitro and in vivo resulting in prolonged effector immune responses.Together the adjuvant effects of the NK1R agonists are highly desired foreffective immunization approaches These studies were performed in thelaboratories of Dr. Adriana Larregina, M.D., Ph.D., research assistantprofessor in the departments of Dermatology and Immunology, University ofPittsburgh School of Medicine.ImmuneRegen and the University have negotiated a license agreement thatsupports ImmuneRegen's vaccine development program In this license,ImmuneRegen obtains rights to use Dr. Larregina's research data as well asa license to the University's ownership interest in a patent recentlyfiled by ImmuneRegen in support of Homspera's intellectual propertyportfolio.ImmuneRegen is developing Homspera, the NK1R-specific analog of theendogenous neuropeptide Substance P (SP), as a potential vaccineadjuvant. Initial studies by ImmuneRegen have revealed adjuvant activityfor Homspera with influenza virus vaccines, resulting in greater antibodyresponses and corresponding protection from challenges with relatedviruses. Follow-up studies evaluating different treatment routes and anumber of experimental vaccines have confirmed this adjuvant effect ofHomspera. "Substance P has been reported to activate the innate immune system andhas been hypothesized to have many roles in the body," said Hal Siegel,Ph.D., ImmuneRegen Vice President and Chief Scientific Officer. "Previousstudies of Homspera have shown increased antibody responses to bothinfluenza vaccination and model antigens, but these are the first detailedstudies to demonstrate this adjuvant activity extends to aspects ofcellular immunity."About ImmuneRegen BioSciences Inc.ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR BioSciencesHoldings, Inc.

(OTCBB: IRBS), is a development-stage biotechnology companyfocused on the research, development and licensing of Homspera and itsderivatives. Homspera is an adult stem cell active compound that in studyresults has been shown to regenerate and strengthen the immune system andenhance wound healing. Viprovex(R), a derivative of Homspera, is beingdeveloped for potential use against infectious diseases as a stand-aloneor combination therapy and as a vaccine adjuvant. To advance its mission,the Scottsdale, Arizona-based company has forged numerous studypartnerships with industry and academic leaders, including CelgeneCellular Therapeutics, HemoGenix, Lovelace Respiratory Research Instituteand Virion Systems. For more information, please visit about ImmuneRegen's future expectations, including statementsabout the potential use and scientific results for ImmuneRegen's drugcandidates, science and technology, and all other statements in this pressrelease other than historical facts, are "forward-looking statements"within the meaning of Section 27A of the Securities Act of 1933, Section21E of the Securities Exchange Act of 1934, and as that term is defined inthe Private Securities Litigation Reform Act of 1995.

ImmuneRegen intendsthat such forward-looking statements be subject to the safe harborscreated thereby. These future events may not occur as and when expected,if at all, and, together with ImmuneRegen's business, are subject tovarious risks and uncertainties. ImmuneRegen's actual results could differmaterially from expected results as a result of a number of factors,including the uncertainties inherent in research and developmentcollaborations, pre-clinical and clinical trials and product developmentprograms (including, but not limited to the fact that future results orresearch and development efforts may prove less encouraging than currentresults or cause side effects not observed in current pre-clinicaltrials), the evaluation of potential opportunities, the level of corporateexpenditures and monies available for further studies, capital marketconditions, and others set forth in ImmuneRegen's periodic report on Form10-KSB for the year ended December 31, 2008 as filed with the Securitiesand Exchange Commission. There are no guarantees that any of ImmuneRegen'sproposed products will prove to be commercially successful.